Top in endocrinology: Semaglutide as obesity treatment, cognitive dysfunction in diabetes

A recent trial demonstrated that weekly semaglutide injections were associated with substantial weight loss in patients with obesity. It was the top story in endocrinology last week.

Another top story was about the use of eye imaging methods for assessing cognitive dysfunction in individuals with type 1 diabetes.

Read these and more top stories in endocrinology below:

Weekly semaglutide injection associated with substantial weight loss in obesity

Adults with obesity assigned the GLP-1 receptor agonist semaglutide experienced substantial weight loss compared with placebo, with more than half of participants losing 15% of body weight, according to data from the STEP 1 study. Read more.

Eye imaging may reveal cognitive dysfunction risk in type 1 diabetes

Noninvasive scans of retinal thickness and vasculature may be used in risk assessment for cognitive dysfunction for adults with type 1 diabetes, according to study data. Read more.

Hyperglycemia, male sex, older age, not HbA1c, related to higher COVID-19 mortality risk

Among adults with type 2 diabetes hospitalized with COVID-19, men, older adults and those with hyperglycemia had increased risks for mortality, but no link was found between mortality and HbA1c, race or ethnicity, according to data from New York. Read more.

Bihormonal artificial pancreas system improves time in range, reduces hypoglycemia

Adults with type 1 diabetes using a fully closed-loop, bihormonal artificial pancreas experienced improved glucose response compared with insulin pump therapy without the need to provide meal or exercise announcements, outpatient data show. Read more.

Control, trust common themes for patients and nurses with inpatient insulin pump use

Control, knowledge, communication and trust are four themes patients and nurses focused on when discussing a patient’s insulin pump self-management during hospitalization, according to study data. Read more.